Update
$Moleculin Biotech(MBRX.US$ Moleculin Announces Additional Positive Preliminary Interim Data From Aml Clinical Trial! 89% Of Crc's Were Subjects With "Poor Prognosis" Cytogenetics and/or Mutations in Study! Annamycin Continues to Demonstrate No Cardiotoxicity! Current Median Durability of Response (Mdor) of Crc's = 6 Months and Increasing (N=9) in Study
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
